PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28985259-4	2018	Warfarin use was associated with a non-significant increase in risk of major bleeding compared with no antithrombotic therapy (RR 1.26, 95% CI 0.99-1.52, I2 = 0.0%, n = 7) and aspirin (RR 1.20, 95% CI 0.91-1.50, I2 = 0.0%, n = 5).	Warfarin	0-8	ribonucleotide reductase catalytic subunit M1	Homo sapiens	127-131	
28985259-4	2018	Warfarin use was associated with a non-significant increase in risk of major bleeding compared with no antithrombotic therapy (RR 1.26, 95% CI 0.99-1.52, I2 = 0.0%, n = 7) and aspirin (RR 1.20, 95% CI 0.91-1.50, I2 = 0.0%, n = 5).	Warfarin	0-8	ribonucleotide reductase catalytic subunit M1	Homo sapiens	185-189	
28655151-8	2018	Thromboembolism occurred in one patient (0.15%) receiving NOAC and in two patients (0.14%) receiving warfarin (risk ratio (RR) 1.07; 95% confidence interval (CI) 0.10-11.81).	Warfarin	101-109	ribonucleotide reductase catalytic subunit M1	Homo sapiens	111-128	
26871818-6	2016	Pooling the results showed that warfarin use was associated with higher risk of any stroke (RR 1.50, 95% CI: 1.13-1.99).	Warfarin	32-40	ribonucleotide reductase catalytic subunit M1	Homo sapiens	92-96	
26871818-8	2016	Warfarin heightened overall bleeding risk (RR 1.27, 95% CI: 1.03-1.56), but not death (RR 0.67, 95% CI: 0.37-1.21).Among patients with atrial fibrillation undergoing hemodialysis, use of warfarin is associated with a higher risk of hemorrhagic stroke, but did not increase overall mortality.	Warfarin	0-8	ribonucleotide reductase catalytic subunit M1	Homo sapiens	43-47